Award
National Institute on Drug Abuse 5R01DA057282-02
Clinical Pharmacology of Nicotine Enantiomers
Recipient
Not specified
Award Amount
$700,343.00
Ceiling
$700,343.00
Awarded
May 28, 2024
Identifier
5R01DA057282-02
Award for a clinical pharmacology study on nicotine enantiomers to support FDA regulation of synthetic nicotine products.
Description
This project involves a human clinical pharmacology study comparing pharmacokinetics, metabolism, subjective, cardiovascular effects, and self-administration of (S)-, (R)-, and racemic nicotine in experienced electronic cigarette users. The study aims to inform FDA regulation of synthetic nicotine products.